Goldfinch Bio Adds Kyle Kuvalanka, Lori Rudolph-Owen to C-Suite

Posted by |2020-04-30T13:05:14-07:00April 30th, 2020|

Goldfinch Bio has appointed Kyle Kuvalanka to serve as chief financial and chief operating officer. His experience includes positions at Syros Pharmaceuticals, Blueprint Medicines (NASDAQ: BPMC), and Takeda Pharmaceutical (NYSE: TAK). In other moves, Cambridge, MA-based Goldfinch promoted Lori Rudolph-Owen to chief development officer. She joined the company in 2018 as senior vice president of […]

Adicet Aims to Advance CAR-T Therapies in Reverse Merger with resTORbio

Posted by |2020-04-29T14:40:42-07:00April 29th, 2020|

Adicet Bio, a privately held preclinical biotech looking to move ahead its “off-the-shelf” CAR-T cell therapies, has struck a deal with struggling resTORbio to use its Nasdaq listing as a backdoor to the public markets. The companies on Wednesday announced an agreement to combine in a type of transaction sometimes referred to as a “reverse […]

Amag Pharma Appoints Rainier’s Myers to Succeed CEO William Heiden

Posted by |2020-04-28T16:25:10-07:00April 28th, 2020|

AMAG Pharmaceuticals (NASDAQ: AMAG) on Tuesday announced Scott Myers has been appointed its new CEO. Myers was most recently CEO of bladder cancer drug developer Rainier Therapeutics. Previously he served as CEO of Cascadian Therapeutics, which was acquired by Seattle Genetics (NASDAQ: SGEN) in 2018. He also spent time as CEO of medical device company […]

Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill

Posted by |2020-04-27T17:42:10-07:00April 27th, 2020|

Many patients with Parkinson’s disease take a combination medication called levodopa/carbidopa to control their symptoms, but over time, experience “off” episodes in which the tremor, slowed movement, and difficulty walking that characterize the disorder occur. Now the FDA has approved a Neurocrine Biosciences (NASDAQ: NBIX) drug intended to be taken along with levodopa/carbidopa to extend […]

Early Bird Sale Ends Today for Xcelerating Life Sciences Boston: Biopharma’s Future in Digital Health

Posted by |2020-04-27T03:30:06-07:00April 24th, 2020|

Learn how digital tech is accelerating medical breakthroughs by registering your team to attend Xcelerating Life Sciences Boston: Biopharma’s Future in Digital Health. The early bird sale for the online conference and networking event ends this Friday, April 24 at midnight. This is your last chance to save! The May 13, 2020 forum will explore […]

ORIC Pharma Gets $120M in IPO to Advance Drug-Resistant Cancer Therapies

Posted by |2020-04-23T20:47:34-07:00April 23rd, 2020|

ORIC Pharmaceuticals followed in the footsteps of the other biotechs that have managed to make their public debut this month, selling more shares than it expected for a haul of $120 million. The South San Francisco, CA-based company—whose name is an acronym for “overcoming resistance in cancer”—priced its IPO late Wednesday, offering 7.5 million shares […]

Biogen Pushes Finalized Filing for Alzheimer’s Drug to Third Quarter

Posted by |2020-04-22T13:35:11-07:00April 22nd, 2020|

Biogen last year said it would ask the FDA to review its potential Alzheimer’s disease treatment, aducanamab, sometime in “early” 2020. The submission is being made under a rolling review, in which sections of an application are filed as they are completed rather than all at once. Now the Cambridge, MA-based company says the regulatory […]

Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19)

Posted by |2020-04-22T02:00:19-07:00April 22nd, 2020|

The start of a potentially big biomedical breakthrough is blooming within all of us. Drug research aiming to turn bacteria into microbiome therapies now spans programs aiming to address gut disorders, autism, cancer, and more. Given the number of late-stage and mid-stage studies expected to report data in 2020—assuming they stay on track amid the […]

War Paint to Bone Paint: MIT Spinout Aims to Transform Regenerative Meds

Posted by |2020-04-21T02:00:10-07:00April 21st, 2020|

Driven by 20 years in the military, the CEO of Theradaptive hopes his firm’s regenerative “paint” technology platform can transform bone repair, spinal fusion, and sports medicine. The Boston-based firm, spun out of MIT, has a computational platform it says turns recombinant proteins into material-binding variants that behave like a paint. This can then be […]

Seattle Genetics Gets Early FDA Nod for Breast Cancer Combo Drug

Posted by |2020-04-20T03:30:08-07:00April 18th, 2020|

Seattle Genetics on Friday received its third FDA approval, a regulatory nod for a breast cancer drug for patients with an especially aggressive form of the disease, four months ahead of schedule. The Bothell, WA-based biotech earned the earlier-than-expected decision for its oral drug tucatinib (Tukysa), when taken in combination with the chemotherapies trastuzumab and […]

COVID-19 Vax Efforts Aim to Balance Speed, Efficacy in Race to Market

Posted by |2020-04-17T15:40:08-07:00April 17th, 2020|

If Peter Marks had a magic wand to perfect the sophisticated process that takes a new vaccine from idea to reality, the US could have a way to prevent some people from COVID-19 infection in nine months to one year. In the real world, the journey to a vaccine OK’d under emergency guidelines is more […]

TearClear Taps Former Shire Executive Robert Dempsey as CEO

Posted by |2020-04-16T08:17:22-07:00April 16th, 2020|

Eye drug developer TearClear has appointed Robert Dempsey to serve as its CEO. Demsey was most recently global head of ophthalmology at Shire, which was acquired by Takeda Pharmaceutical (NYSE: TAK). TearClear says Dempsey’s hire comes as the company approaches the initial close of a Series B round of funding that could reach up to […]
Go to Top